As consumer awareness of the gut microbiome continues to grow, supplement brands are increasingly seeking scientifically documented ingredients that deliver more than basic digestive support. Among these, B. lactis Lafti® B94 stands out as a well-characterised probiotic strain backed by an extensive body of mechanistic and clinical research, providing opportunities for innovation in gut health and adjacent wellness categories.
Developed by Lallemand Health Solutions, Lafti® B94 has been investigated through a comprehensive scientific programme including 11 clinical trials, 11 mechanistic studies and 22 published studies. The strain has undergone a rigorous safety evaluation that includes genomic characterisation, antibiotic resistance screening, toxicological assessments and human safety studies.
A key differentiator of Lafti® B94 lies in its ability to interact effectively with the gut ecosystem. Research demonstrates that the strain can survive passage through the digestive tract, adhere to intestinal epithelial cells and remain detectable after consumption. Human studies have shown that Lafti® B94 reaches the intestine and persists beyond the supplementation period, supporting its ability to interact with the resident microbiota.
Equally important is its documented synergy with prebiotics. During in vitro screening of 40 bifidobacterial isolates, Lafti® B94 was selected for its capacity to utilise a wide range of prebiotic substrates, including fructo-oligosaccharides (FOS), galacto-oligosaccharides (GOS), inulin and other oligosaccharides. Further in vivo research demonstrated that combining the strain with FOS or inulin enhanced survival and extended retention time in the gastrointestinal tract, highlighting the potential advantages of synbiotic formulations.
Scientific investigations have identified several complementary modes of action that help explain the strain's performance. These include support for gut barrier integrity, competition with opportunistic microorganisms, modulation of immune responses, enhancement of short-chain fatty acid production and optimisation of carbohydrate and protein digestion. Notably, studies have reported increased acetate production and cross-feeding pathways associated with butyrate generation, mechanisms that contribute to a healthier and more resilient gut environment.
Clinical research further reinforces the strain's relevance for digestive health applications. Studies conducted in infants, children, adolescents and adults have explored the use of Lafti® B94 alone or combined with prebiotics across a variety of gastrointestinal settings. Published findings have reported benefits related to digestive comfort, gut motility, occasional diarrhoea management and support during specific gastrointestinal challenges. Additional clinical work has expanded investigation into metabolic health applications, demonstrating the versatility of the strain beyond traditional digestive categories.
For product developers, Lafti® B94 offers considerable formulation flexibility. The strain is available in a range of delivery formats including powders, capsules, sachets, chewable tablets and orodispersible presentations, enabling manufacturers to create differentiated consumer experiences across multiple market segments.
As the microbiome category evolves from single-ingredient solutions towards ecosystem-based approaches, Lafti® B94 provides a strong scientific foundation for both probiotic and synbiotic innovations. By combining documented mechanisms of action, clinical evidence and proven compatibility with prebiotic substrates, the strain offers supplement brands a versatile platform for developing next-generation gut health products that meet growing consumer expectations for efficacy, convenience and scientific credibility.
Contact Lallemand Health Solutions to learn more: healthsolutions@lallemand.com
